Top Page
Telix Pharmaceuticals
(Sydney:TLX)
Telix Pharmaceuticals (TLX) vs. iShares MSCI Australia ETF (EWA)
Telix Pharmaceuticals Business Overview & Revenue Model
Telix Pharmaceuticals Earnings Call Summary
Telix Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.19B | 783.21M | 502.55M | 160.10M | 7.60M | 5.21M |
| Gross Profit | 674.14M | 509.68M | 314.39M | 29.34M | -29.77M | -16.88M |
| EBITDA | 85.71M | 92.55M | 22.97M | -92.84M | -70.07M | -54.20M |
| Net Income | 34.76M | 49.92M | 5.21M | -104.08M | -80.51M | -44.89M |
Balance Sheet | ||||||
| Total Assets | 1.19B | 1.52B | 398.30M | 255.35M | 109.81M | 157.82M |
| Cash, Cash Equivalents and Short-Term Investments | 207.16M | 710.35M | 123.24M | 116.33M | 22.04M | 77.94M |
| Total Debt | 418.25M | 581.45M | 17.45M | 10.45M | 2.54M | 2.21M |
| Total Liabilities | 768.01M | 948.22M | 249.39M | 178.44M | 106.17M | 78.81M |
| Stockholders Equity | 421.94M | 568.21M | 148.91M | 80.01M | 2.16M | 79.02M |
Cash Flow | ||||||
| Free Cash Flow | 5.92M | 9.00M | 13.09M | -77.83M | -60.67M | 1.64M |
| Operating Cash Flow | 36.39M | 43.03M | 23.88M | -63.97M | -59.33M | 1.96M |
| Investing Cash Flow | -497.38M | -135.17M | -25.49M | -17.00M | -2.73M | -1.09M |
| Financing Cash Flow | 630.70M | 638.92M | 10.19M | 174.96M | 2.85M | 34.12M |
Telix Pharmaceuticals Technical Analysis
Telix Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $2.71B | 18.33 | 54.79% | ― | 12.35% | 26.73% | |
| ― | $572.79M | 15.66 | 15.90% | 0.44% | 7.76% | 1.55% | |
| ― | $5.47B | 324.70 | 3.21% | ― | 60.23% | -66.98% | |
| ― | $3.22B | ― | -18.95% | ― | 198.58% | 3.97% | |
| ― | AU$44.16M | ― | -49.72% | ― | ― | 10.78% | |
| ― | $419.50M | ― | -35.86% | ― | ― | -19.21% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Telix Pharmaceuticals Corporate Events
Telix Pharmaceuticals announced the release of 45,584 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business. This release of shares is a strategic move following the acquisition, potentially impacting Telix’s market positioning by enhancing its operational capabilities in the radio-guided surgery sector.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$34.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals announced the release of 1,649,037 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Lightpoint Medical’s SENSEI® radio-guided surgery business. This release, scheduled for November 3, 2025, marks a significant step in the integration of Lightpoint Medical’s technologies, potentially enhancing Telix’s market position in the field of minimally invasive and robotic-assisted surgery.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$23.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals reported a significant revenue increase of 53% year-over-year for Q3 2025, reaching $206 million, and upgraded its FY 2025 revenue guidance to $800-820 million. The company achieved full reimbursement for Gozellix in the U.S. and expanded its Illuccix product approval to 19 European markets. These developments, along with ongoing clinical trials and strategic market launches, position Telix strongly in the precision medicine sector, enhancing its competitive edge and operational capabilities.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$24.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited announced the cessation of certain securities, including share rights and share appreciation rights, due to unmet conditions. This development may impact the company’s capital structure and could have implications for its stakeholders, as it reflects adjustments in the company’s financial and operational strategies.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$24.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited announced the issuance of 80,000 ordinary fully paid securities, effective September 11, 2025. This move reflects the company’s ongoing efforts to enhance its financial structure and support its strategic initiatives, potentially impacting its market positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$24.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited has announced the quotation of new securities on the Australian Securities Exchange (ASX), with a total of 21,815 ordinary fully paid shares being issued. This move is part of the company’s strategic efforts to enhance its capital structure and potentially improve its market position, which could have implications for its stakeholders by increasing the liquidity and visibility of its shares.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$24.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals announced that the U.S. Centers for Medicare & Medicaid Services has granted Transitional Pass-Through payment status for Gozellix, their next-generation PSMA-PET imaging agent for prostate cancer. This designation allows for separate reimbursement under the Hospital Outpatient Prospective Payment System, effective October 1, 2025, and is a key milestone in Telix’s U.S. commercial strategy. Gozellix offers a longer shelf life and extended distribution radius, improving access and efficiency in prostate cancer imaging. The reimbursement status is expected to reduce patient costs and enhance access to advanced imaging, strengthening Telix’s market position as a leader in PSMA-PET/CT imaging.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$34.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Challenger Limited has announced that it has ceased to be a substantial holder in Telix Pharmaceuticals Ltd. This change in holding status was officially communicated to the ASX, indicating a shift in Challenger’s investment strategy or portfolio composition regarding Telix Pharmaceuticals. The announcement may impact stakeholders by altering the perceived market position or investment appeal of Telix Pharmaceuticals.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$23.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals has reached an agreement with the U.S. FDA on the resubmission pathway for its New Drug Application for TLX101-CDx, an investigational imaging agent for glioma, a rare brain cancer. The company plans to resubmit the NDA in Q4 2025, following detailed feedback from the FDA, which includes conducting an additional confirmatory efficacy study. The FDA has acknowledged the unmet medical need and indicated that an expedited review is likely, although TLX101-CDx is not included in Telix’s 2025 revenue guidance as it remains an unapproved product.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$16.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited has announced the quotation of 37,949 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 8, 2025. This move is part of an employee incentive scheme, reflecting the company’s commitment to rewarding its workforce and potentially enhancing its market position by aligning employee interests with shareholder value.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$16.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals announced the release of 41,698 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business. This release, set for 17 September 2025, is in accordance with ASX Listing Rule 3.10A and may impact the company’s market operations by potentially increasing share liquidity and investor interest.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$16.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Challenger Limited has announced that it has ceased to be a substantial holder in Telix Pharmaceuticals Ltd. This change in holding status is significant as it indicates a shift in Challenger’s investment strategy or portfolio composition, potentially impacting Telix’s shareholder structure and market perception.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$16.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Ltd. recently held its earnings call, showcasing a strong performance marked by impressive revenue growth, strategic product expansion, and key acquisitions. The company demonstrated a robust cash position and significant pipeline advancements. However, challenges such as SEC inquiries, gross margin pressures, and competitive pricing were also highlighted.
Telix Pharmaceuticals announced it received a Complete Response Letter from the U.S. FDA regarding its Biologics License Application for TLX250-CDx, a PET agent for diagnosing renal masses. The FDA identified deficiencies in the Chemistry, Manufacturing, and Controls package, requiring additional data and remediation of issues with third-party partners. Despite these setbacks, Telix plans to address the concerns promptly and believes the issues are resolvable. The announcement does not affect the company’s 2025 revenue guidance, as it excludes unapproved products, and Telix will continue providing patient access through an FDA-approved expanded access program.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$25.60 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Ltd. is a company specializing in the development and distribution of radiopharmaceutical products, primarily operating in the biotechnology sector with a focus on oncology and rare diseases. In its interim report for the first half of 2025, Telix Pharmaceuticals reported a significant revenue increase to $390.4 million, a 63% rise from the previous year, driven by organic growth of Illuccix® and the acquisition of RLS. Despite this growth, the company recorded a net loss of $2.3 million, attributed to non-cash interest expenses and increased investments in research and development. Key financial metrics included a gross margin of 53% and an adjusted EBITDA of $21.1 million, reflecting strategic investments in pipeline development and global manufacturing capabilities. Looking ahead, Telix’s management remains focused on advancing its therapeutic pipeline and expanding its market presence, aiming for sustainable long-term growth through continued innovation and strategic acquisitions.
Telix Pharmaceuticals reported strong financial results for the first half of 2025, with a 63% increase in revenue to $390.4 million, driven by strategic investments in commercial infrastructure and R&D. The company is expanding its global manufacturing operations and launching new products, positioning itself for sustainable long-term growth. Despite a loss before tax of $4.8 million due to non-cash finance costs and increased amortization, Telix maintains a positive operating cash flow and continues to invest heavily in its therapeutics pipeline, with significant advancements in clinical trials and product approvals anticipated.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals reported strong revenue growth for the half-year ending June 30, 2025, with total revenue reaching $390.4 million, marking a 63% increase from the previous year. Despite the revenue growth, the company recorded an operating loss of $2.3 million due to increased finance costs and investments in research and development. Telix is positioning itself for long-term growth by expanding its product line and geographic reach, notably through the acquisition of RLS Radiopharmacies and the pending approvals of new products.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.